Derma Science recieves BARDA grant. Delcath faces FDA setback. Gilead acquires Calistoga Pharma Print E-mail
By Staff and Wire Reports   
Tuesday, 22 February 2011 19:38
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 22, 2011.


Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.5 million,16-month grant by the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure. This contract, which is part of the HHS radiological and nuclear threats preparedness strategy, could be extended for a total of five years and up to a total of $14 million. Derma Sciences recently announced positive Phase 2 data in the use of DSC127 in diabetic foot ulcer healing, in which 54% of wounds healed completely in 12 weeks, compared with only 33% of wounds in patients receiving placebo and best standard of care in the intent to treat populations.

Shares of Derma gained 44 cents or 4.55% to $10.10.

Shares of Delcath Systems, Inc. (Nasdaq:DCTH) fell today after the company announced today that it has received a "refusal to file" letter from the FDA for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride. Delcath expects to submit a formal meeting request to the FDA this week and intends to meet with the FDA at the earliest opportunity to discuss the issues raised and to confirm our understanding of the remedies required for the filing to be accepted. Based on management's current understanding of the information in the FDA's letter, the Company intends to resubmit the NDA by September 30, 2011.

Shares dropped $4.29 or 38% to $7.01.

Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it will acquire Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, for $375 million. Calistoga could earn up to an additional $225 million if certain milestones are achieved. Calistoga focuses on the development of medicines to treat cancer and inflammatory diseases such as CAL-101, that may help fight non-Hodgkin's lymphoma and help treat elderly patients in a specific type of leukemia.

"Oncology remains an area of significant unmet medical need and our increased understanding of the genetic basis of cancer allows for the development of disease specific targeted therapies," said Gilead's Chief Scientific Officer Norbert W. Bischofberger. "We are very encouraged by emerging clinical data for CAL-101, and this compound could represent an advance for the treatment of certain hematological cancers."

Cannabis Science, Inc. (OTCBB:CBIS.ob) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells. Cannabis Science, in conjunction with Rockbrook, its Colorado-licensed dispensary, consulted with a variety of cancer patients who were seeking to inform themselves of the current peer reviewed scientific literature, regarding the historical use of cannabis to treat "tumors". Unlike most conventional cancer treatments, cannabis has an outstanding safety profile, and patients in states with medical marijuana laws are able to make an informed decision to legally try various cannabis preparations to determine what is most effective for their particular condition.

Some of these scientifically informed patients have chosen to self-administer Cannabis Science extracts supplied by Rockbrook to treat their own cancers. Cannabis Science is delighted that patients are reporting dramatic improvements in their conditions, including basal cell carcinoma, non-small cell lung cancer accompanied by COPD (chronic obstructive pulmonary disease), ovarian cancer, and glioma.

Shares jumped 3.5 cents or 103% to $0.068.

Vical Incorporated (Nasdaq:VICL) announced today that the company has extended its relationship with the U.S. Naval Medical Research Center (NMRC) to develop its platform technology for the rapid development and production of vaccines against emerging infectious diseases.

Vical received U.S. government funding from Defense Threat Reduction Agency and NMRC in 2010 to support development of its Vaxfectin-formulated DNA vaccine against H1N1 pandemic influenza, which is expected to complete Phase 1 testing in the first quarter of 2011. With additional funding under the extended relationship, Vical will work with NMRC under this contract to establish systems and procedures for the application of Vical's DNA delivery technology, with the goal of protecting military personnel from the threat of new pathogens in the early stages of outbreaks.

Shares rose 8 cents or 4.23% to $1.97.

Omeros Corporation (Nasdaq:OMER) today announced that its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd. has been amended to include addiction and compulsive disorders in the field of use. Omeros' PDE7 program was founded on the Company's discovery of a previously unknown link between PDE7 and any movement disorder, such as Parkinson's disease. Omeros believes that it also is the first to link PDE7 to any addiction or compulsive behavior, and is now advancing PDE7 inhibitors for the treatment of these as well as movement disorders. Omeros is collaborating on this program with both the National Institute on Drug Abuse (NIDA) and The Michael J. Fox Foundation.

OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that its OraQuick HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies with a fingerstick whole blood sample. The fingerstick whole blood claim is the second application to be approved by the FDA for the OraQuick HCV test. The product received an initial approval for use in persons at risk for HCV infection with venous whole blood specimens in June 2010.

Also Tuesday:

Aeterna Zentaris Inc. (NASDAQ: AEZS) TSX: AEZ) a late-stage drug development company specialized in oncology and endocrinology, announced today that it has filed a prospectus supplement dated February 22, 2011 to its U.S. shelf prospectus, dated March 12, 2010, forming part of its U.S. registration statement on Form F-3 with the United States Securities and Exchange Commission as well as a prospectus supplement to its Canadian final base shelf prospectus dated March 12, 2010.


Adherex Technologies Inc.(TSX:AHX) (PINK SHEETS:ADHXF) announced today that the record date for its previously announced rights offering has been changed from 5:00 pm, New York City time on February 24, 2011 to March 2, 2011, at which time the subscription period will commence.

AtheroNova Inc. (OTCBB: AHRO) a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that the Company's second round preclinical atherosclerotic plaque regression study has commenced at The David Geffen School of Medicine at UCLA.

China Cord Blood Corporation (NYSE:CO), the first and largest cord blood banking operator in China, today announced the results of its 2010 Annual General Meeting, which was held on February 18, 2011, in Hong Kong.

CytoSorbents Corporation (OTCBB: CTSO) announced that it has raised an additional $1.25 million from the sale of its convertible notes, achieving its maximum targeted goal under these terms.

Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has launched FibreZyme® G200, a next generation, high performance enzyme designed to improve paper quality and improve the economics of various pulp and paper manufacturing processes.

eHealth, Inc. (NASDAQ: EHTH) announced that eHealthInsurance Services, Inc., its wholly-owned subsidiary, has been awarded the contract to add a web-based Provider Directory Service to the state of Massachusetts' Health Connector.Massachusetts selected eHealth to help expand consumer search options on the state's online health insurance exchange with a new tool that narrows a plan search by the customer's personal physician preference.

Entest BioMedical Inc. (OTCBB: ENTB) announced that it has signed a letter of intent (LOI) to acquire three veterinary hospitals located in Southern California.

eResearchTechnology, Inc. (ERT or the Company), (Nasdaq:ERES), a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, announced today the appointment of Eric Ian Schwartz as Executive Vice President and Chief Legal Officer effective February 22, 2011.

FONAR Corporation (NASDAQ: FONR) today announced its financial results for the second quarter of fiscal 2011, which ended December 31, 2010.

Fresh Start Private (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, announced today that it is processing over $1.2 Million dollars in insurance claims at its Orange Country clinic.

Given Imaging Ltd. (NASDAQ: GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced that the U.S. Food and Drug Administration (FDA) has cleared revised labeling regarding the use of the SensorBelt in patients with a Body Mass Index (BMI) of up to 43.3 kg/m2, reflecting the results of a recent clinical trial.

Global NuTech, Inc. (OTCBB:BOCL) announced today that its Joint Venture partner, HIGA Corporation, has entered into an agreement with Sysna, Inc. to distribute a unique foam rubber device designed to securely fit a Blue Tooth earpiece in the user's ear.

Hiru Corporation (PINK SHEETS:HIRU), subsidiary Jiangxi Shuangshi Animal Health Products Co.'s (Shuangshi AHP) sales department and after-sales customer service departments recently hosted a major successful product promotion in northern China.

Inovio Pharmaceuticals, Inc. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will make presentations at two partnering and scientific conferences.

Luminex Corporation (Nasdaq:LMNX), today announced for the third consecutive year it has been named one of the 25 Fastest-Growing Technology Companies in America by Forbes.

MMRGlobal, Inc. (OTCBB: MMRF) today announced it will begin shipping the Company's MMRPro 550 document imaging and management solution starting in April.

Medisafe 1 Technologies Corp. (OTCBB: MFTH)
, a developer of patented technologies that physically prevent unauthorized administration of prescription medications, today announced the signing of an LOI to secure a $5,000,000 Equity Funding Facility with Centurion Private Equity, LLC, an institutional investor managed by Roswell Capital Partners, LLC.

MMRGlobal, Inc. (OTCBB: MMRF) today announced that it is introducing an electronic point-of-sale system for physician offices, healthcare professionals and hospital systems.

Pegasystems Inc. (NASDAQ: PEGA), the leader in business process management (BPM) solutions, today unveiled a significant upgrade to its customer relationship management (CRM) offerings.

Rosetta Genomics, Ltd. (NASDAQ: ROSG) today announced the closing of an initial public offering (IPO) of its majority-owned subsidiary, Rosetta Green, in Israel which raised gross proceeds of 21,900,960 NIS ($6.06 million).

Rural/Metro Corporation (NASDAQ: RURL), a leading national provider of ambulance and private fire protection services, announced today that Michael DiMino, President and Chief Executive Officer, is scheduled to present at the RBC Capital Markets' Healthcare Conference on March 3, 2011 at The New York Palace Hotel in New York City.

SensiVida Medical Technologies, Inc. (PINKSHEETS: SVMT), a developer and provider of minimally invasive digital diagnostic technologies and devices, announced today that the company has received a notice of allowance from the U. S. Patent and Trademark Office for one of its key patent applications, titled "Minimally Invasive Allergy Testing System."

Simulated Environment Concepts (PINKSHEETS: SMEV), the manufacturer and developer of medical, aesthetic, weight loss, wellness and slimming equipment, announced today that its 1st Quarterly Shareholder Perception Study has already resulted in the company preparing to make adjustments in line with shareholder request.

Stereotaxis, Inc. (Nasdaq:STXS) today announced that Joseph D. Keegan, Ph.D., 55, was elected to its Board of Directors.

TRIMEDYNE, INC. (OTCBB: TMED) today reported its financial results for the quarter ended December 31, 2010.

Verenium Corporation (Nasdaq:VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that it will release 2010 fourth quarter and year-end financial results on Tuesday, March 1, 2011 after market close.

VMware, Inc. (NYSE: VMW), the global leader in virtualization and cloud infrastructure, today announced that Spectrum Health has chosen VMware ThinApp™ to provide fast and efficient access to point-of-care applications, electronic medical records (EMR) and patient data from their cloud computing environment.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter